Compare Cassava Sciences Inc (FLNA) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Weibo Corp — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Weibo Corp trades at $6.51 (market cap $1.56B). The key difference: Weibo Corp is far larger — about 39.6× Cassava Sciences Inc's market cap, and Weibo Corp pays a 9.47% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Weibo Corp for 102 Days on average.
| FLNA | WB | |
|---|---|---|
Market Cap | $39.40M | $1.56B |
Volume | 759,018 | 812,503 |
Sector | Health | Media |
52-Week High | $4.64 | $12.37 |
52-Week Low | $0.68 | $6.33 |
Typical Hold Time | 37 Days | 102 Days |
Enterprise Value | -$43.28M | $786.69M |
Dividend Yield | — | 9.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Weibo (WB) trades at $6.48, down 0.15% with bearish technical signals. The stock shows attractive valuation metrics including a P/E of 5.36 and P/B of 0.4, while maintaining strong profitability with 73.36% gross margins. Recent earnings show mixed performance with Q2 2026 beating expectations but Q4 2025 and Q1 2026 missing estimates. Cash flow trends indicate volatility with a significant net outflow in 2024 followed by recovery in 2025.
Weibo presents as a deep-value opportunity with compelling valuation multiples, though growth concerns persist amid declining user metrics and advertising challenges. Analyst sentiment remains divided with 40.9% buy ratings versus 45.5% hold, reflecting uncertainty about the company's ability to maintain relevance against intensifying competition in social media.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
